BioSpace News Archive

Arch Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd , 2022, for the treatment of relapsed/refractory multiple myeloma (r/r MM).

22nd Century Group, Inc. today announced the appointment of James A. Mish to its Board of Directors (Board).

Biocept, Inc announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.

Catalent today announced that it will release financial results for the second quarter of fiscal year 2022 ended December 31, 2021, before the market open on Tuesday, February 1, 2022.

After nearly a year in intensive care at Children’s Hospital of Philadelphia, 10-month-old conjoined twins Addison and Lilianna Altobelli were successfully separated by CHOP surgeons on October 13, 2021.

Medivir AB (Nasdaq Stockholm: MVIR-B) today announces that an e-poster entitled “Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver” will be presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit 3-4 February.

ELEVAI LABS, INC. is pleased to announce that it has signed a non-exclusive global distributor and trademark license agreement with leading Australian headquartered aesthetic device company DermapenWorld™ (“Dermapen”).

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2021 on Thursday, 10 February 2022.

Breaking research published today in AACC’s Clinical Chemistry journal shows that a new test can measure the amount of DNA damage in sperm with greater accuracy than current tests.

Today, Eurofins (Paris:ERF) subsidiary empowerDX has launched PFAS Exposure™ in the United States, the first direct to consumer at-home test to determine levels of PFAS in a person’s blood and measure 47 of the PFAS “forever chemical” compounds.